Where does thoracic radiotherapy fit in extensive-stage #SCLC in the immunotherapy era?
Dr Huiqi Yang: consolidation RT should be offered to good responders after chemotherapy, but its role following chemoimmunotherapy remains uncertain.
#BTOGSCLC26 #LCSM

Could radiopharmaceuticals become another way to target #SCLC?
Dr Toby Talbot explains how a radioisotope can be delivered to tumour-specific targets – a similar principle to an ADC, but with radiation replacing the drug payload.
#BTOGSCLC26 #LCSM

If SCLC is changing, and brain-directed radiotherapy is changing, then brain-directed RT in SCLC is also changing.

Waleed Mohammed tackles one of today’s controversies: the evolving role of PCI, MRI surveillance and SRS/SRT.

#BTOGSCLC26 #SCLC #LCSM

Professor Fiona Blackhall explores ADCs in relapsed SCLC at #BTOGSCLC26.
Two phase III B7-H3 ADC trials have reset expectations, but the next questions are just as important: how do we select patients, sequence treatments and manage toxicity as the SCLC pathway continues to evolve?

Sean Dulloo reviews the rapidly evolving role of T-cell engagers in SCLC at #BTOGSCLC26.
Tarlatamab is the first therapy to demonstrate a survival advantage over chemotherapy in relapsed SCLC, with activity also seen in patients with brain metastases.

Early treatment impacts survival in extensive-stage #SCLC.
Prof Samreen Ahmed highlights the rapid attrition after first-line therapy – real-world data suggest only 21.9% of patients transition to second-line treatment.
Her message: keep the threshold for treatment low.
#BTOGSCLC26 #LCSM

At #BTOGSCLC26, Emma Wingate asks us to move beyond “Who is fit enough?” to “Who could become fit enough?”

Patient selection is about more than performance status. Optimisation and prehabilitation can help more people access, complete and benefit from treatment, while preserving quality of life.

“Large volumes can still be curatively treated.”
Hannah Bainbridge discusses optimising thoracic radiotherapy in limited-stage #SCLC – from staging and patient fitness to planning, dose, motion management and adaptive treatment.
#BTOGSCLC26 #LCSM

Session 2 on Limited Stage SCLC is chaired by Samreen Ahmed and starts with Tom Combellack talking about "What Is Resectable in SCLC?"
#BTOGSCLC26

In the final presentation of the first #BTOGSCLC26 session, Riyaz Shah asks "Is Long-Term Survival in SCLC Achievable?"

Speed matters in #SCLC.
Emma Halkyard shares Greater Manchester’s work to accelerate the diagnostic pathway: if SCLC is suspected, alert everyone involved in the pathway as early as possible.
A system-wide, multi-professional approach is key.
#BTOGSCLC26 #LCSM

Kicking off the session on Diagnosing and the Changing Face SCLC, chaired by Tom Newsom-Davis is Neal Navani on SCLC State of the Nation: NLCA 2026 #BTOGSCLC26

Ready to start the day at #BTOGSCLC26 - we’ll be posting key highlights throughout the day so follow the hashtag